Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Ligand (LGND) Q4 Earnings & Revenues Top, 2018 View Solid

2018-02-22 zacks
Ligand Pharmaceuticals Incorporated (LGND - Free Report) reported fourth-quarter 2017 adjusted earnings of $1.31 per share, significantly up 77% from the year-ago figure of 74 cents. The bottom line also beat the Zacks Consensus Estimate of $1.06. (90-0)

Biotechs: Still Well Placed For More Gains

2018-02-20 seekingalpha
Big Pharma has to build out pipelines in new areas, and M&A is a compelling alternative. (719-3)

SPPI / Spectrum Pharmaceuticals, Inc. / Renaissance Technologies LLC - 3G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SPECTRUM PHARMACEUTICALS, INC. ---------------------------------------------------------------------------- (Name of Issuer) common stock ---------------------------------------------------------------------------- (Title of Class of Securities) 84763A108 ---------------------------------------------------------------------------- (CUSIP Number) Decemb

SPPI / Spectrum Pharmaceuticals, Inc. / Renaissance Technologies LLC - 3G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SPECTRUM PHARMACEUTICALS, INC. ---------------------------------------------------------------------------- (Name of Issuer) common stock ---------------------------------------------------------------------------- (Title of Class of Securities) 84763A108 ---------------------------------------------------------------------------- (CUSIP Number) Decemb

SPPI / Spectrum Pharmaceuticals, Inc. / Consonance Capital Management LP - CONSONANCE CAPITAL MANAGEMENT LP (Passive Investment)

2018-02-14 sec.gov
sppi_21418.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SPECTRUM PHARMACEUTICALS INC (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 84763A108 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [   ] Rule 13d-1(c) [   ] Rule 13d-1(d) * T

SPPI / Spectrum Pharmaceuticals, Inc. / Consonance Capital Management LP - CONSONANCE CAPITAL MANAGEMENT LP (Passive Investment)

2018-02-14 sec.gov
sppi_21418.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SPECTRUM PHARMACEUTICALS INC (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 84763A108 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [   ] Rule 13d-1(c) [   ] Rule 13d-1(d) * T

SPPI / Spectrum Pharmaceuticals, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-14 sec.gov
spectrumpharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 5 )*       Name of issuer:  Spectrum Pharmaceuticals Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  84763A108     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule

SPPI / Spectrum Pharmaceuticals, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-14 sec.gov
spectrumpharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 5 )*       Name of issuer:  Spectrum Pharmaceuticals Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  84763A108     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule

SPPI / Spectrum Pharmaceuticals, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-14 sec.gov
spectrumpharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 5 )*       Name of issuer:  Spectrum Pharmaceuticals Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  84763A108     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule

SPPI / Spectrum Pharmaceuticals, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-14 sec.gov
spectrumpharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 5 )*       Name of issuer:  Spectrum Pharmaceuticals Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  84763A108     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule

SPPI / Spectrum Pharmaceuticals, Inc. / FMR LLC / Fidelity - 3G (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 0 SPECTRUM PHARMACEUTICALS INC COMMON STOCK Cusip #84763A108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #84763A108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,059,578 Item 6: 0 Item 7: 7,035,678 Item 8: 0 Item 9: 7,035,678 Item 11: 6.

SPPI / Spectrum Pharmaceuticals, Inc. / FMR LLC / Fidelity - 3G (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 0 SPECTRUM PHARMACEUTICALS INC COMMON STOCK Cusip #84763A108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #84763A108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,059,578 Item 6: 0 Item 7: 7,035,678 Item 8: 0 Item 9: 7,035,678 Item 11: 6.

SPPI / Spectrum Pharmaceuticals, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G (Passive Investment)

2018-02-08 sec.gov
    UNITED STATES OMB APPROVAL   SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145   Washington, D.C. 20549 Expires: February 28, 2009     Estimated average burden hours per response. . . . . . . .10.4   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No.   )*   Spectrum Pharmaceuticals, Inc. (Name of Issuer) Common (Title of Class of Securities) 84763A108 (CUSIP Number) January 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

SPPI / Spectrum Pharmaceuticals, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G (Passive Investment)

2018-02-08 sec.gov
    UNITED STATES OMB APPROVAL   SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145   Washington, D.C. 20549 Expires: February 28, 2009     Estimated average burden hours per response. . . . . . . .10.4   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No.   )*   Spectrum Pharmaceuticals, Inc. (Name of Issuer) Common (Title of Class of Securities) 84763A108 (CUSIP Number) January 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

Spectrum Pharmaceuticals: What Does The Recent Management Streamlining Signify?

2018-02-07 seekingalpha
Despite an illustrious career at Spectrum, CEO Rajesh Shrotriya was the subject of a complaint by investors. (67-0)


CUSIP: 84763A108